Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases

dc.authoridKimyon Comert, Günsu/0000-0003-0178-4196
dc.authoridKuru, Oguzhan/0000-0002-4497-7222
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridDurmuş, Yasin/0000-0002-5404-0118;
dc.authorwosidKaralok, Alper/D-5515-2018
dc.authorwosidKimyon Comert, Günsu/AGK-3090-2022
dc.authorwosidTuran, Ahmet Taner/HJZ-4519-2023
dc.authorwosidKuru, Oguzhan/HJA-3308-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidDurmus, Yasin/AAO-8292-2021
dc.authorwosidDurmuş, Yasin/AAP-6729-2021
dc.contributor.authorBoyraz, Gokhan
dc.contributor.authorDurmus, Yasin
dc.contributor.authorCicin, Irfan
dc.contributor.authorKuru, Oguzhan
dc.contributor.authorBostanci, Esra
dc.contributor.authorComert, Gunsu Kimyon
dc.contributor.authorSahin, Hanifi
dc.date.accessioned2024-06-12T11:11:51Z
dc.date.available2024-06-12T11:11:51Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurposeTo investigate the clinico-pathological prognostic factors and treatment outcomes in patients with ovarian yolk sac tumors (YST).MethodsA multicenter, retrospective department database review was performed to identify patients with ovarian YST who underwent surgery between 2000 and 2017 at seven Gynecologic Oncology Centers in Turkey.ResultsThe study group consisted of 99 consecutive patients with a mean age of 23.9years. While 52 patients had early stage (stage I-II) disease, the remaining 47 patients had advanced stage (stage III-IV) disease. Theuterus was preserved in 74 (74.8%) of the cases. The absence of gross residual disease following surgery was achieved in 76.8% of the cases. Of the 54 patients with lymph node dissection (LND), lymph node metastasis was detected in 10 (18.5%) patients. Of the 99 patients, only 3 patients did not receive adjuvant therapy, and most of the patients (91.9%) received BEP (bleomycin, etoposide, cisplatin) chemotherapy. Disease recurred in 21 (21.2%) patients. The 5-year disease-free survival (DFS) and overall survival (OS) in the entire cohort were 79.2% and 81.3%, respectively. In multivariate analysis, only residual disease following initial surgery was found to be significantly associated with DFS and OS in patients with ovarian YST (p=0.026 and p=0.001, respectively).ConclusionsOur results demonstrate the significance of achieving no visible residual disease in patients with ovarian YST. Fertility-sparing approach for patients with no visible residual disease affected neither DFS nor OS. Although high lymphatic involvement rate was detected, the benefit of LND could not be demonstrated.en_US
dc.identifier.doi10.1007/s00404-019-05160-6
dc.identifier.endpage182en_US
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.issue1en_US
dc.identifier.pmid30982145en_US
dc.identifier.scopus2-s2.0-85064343620en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage175en_US
dc.identifier.urihttps://doi.org/10.1007/s00404-019-05160-6
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22957
dc.identifier.volume300en_US
dc.identifier.wosWOS:000471155100022en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofArchives Of Gynecology And Obstetricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOvarian Canceren_US
dc.subjectYolk Sac Tumorsen_US
dc.subjectGerm Cell Tumorsen_US
dc.subjectEndodermal Sinus Tumorsen_US
dc.subjectResidual Diseaseen_US
dc.subjectGerm-Cell Tumorsen_US
dc.subjectEndodermal Sinus Tumoren_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.titlePrognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 casesen_US
dc.typeArticleen_US

Dosyalar